Potentiation of vincristine toxicity by itraconazole in children with lymphoid malignancies

被引:50
作者
Kamaluddin, M
McNally, P
Breatnach, F
O'Marcaigh, A
Webb, D
O'Dell, E
Scanlon, P
Butler, K
O'Meara, A
机构
[1] Our Ladys Hosp Sick Children, Dept Haematol, Dublin, Ireland
[2] Our Ladys Hosp Sick Children, Dept Oncol, Dublin, Ireland
[3] Our Ladys Hosp Sick Children, Dept Neurol, Dublin, Ireland
[4] Our Ladys Hosp Sick Children, Dept Infect Dis, Dublin, Ireland
关键词
ALL; children; itraconazole; neurotoxicity; vincristine;
D O I
10.1080/080352501317061675
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Eight consecutive paediatric patients with acute lymphoblastic leukaemia (ALL) (n = 7) and T-cell non-Hodgkin's lymphoma (NHL) (n = 1) presenting within a 5-wk interval were started on a standard induction protocol which included weekly treatment with vincristine for 4 wk. Itraconazole was commenced as antifungal prophylaxis, 1-21 d after the first injection of vincristine. Within 2 to 4 wk, enhanced vincristine neurotoxicity was noted in all patients, abdominal cramps and constipation occurred most frequently, and one patient developed a bowel perforation associated with paralytic ileus. Hyponatraemia associated with SIADH was observed in three patients and four patients developed seizures. An additional patient with B cell NHL developed seizures 5 d after an injection of vincristine. Recovery was complete in all patients and ranged from 2 d to 15 wk. Conclusion: The extent and consistency of adverse effects documented in this study support the recommendation that concurrent administration of vincristine and itraconazole should be avoided.
引用
收藏
页码:1204 / 1207
页数:4
相关论文
共 17 条
[1]  
Bohme A, 1995, ANN HEMATOL, V71, P311, DOI 10.1007/BF01697985
[2]  
BORGERS M, 1980, REV INFECT DIS, V2, P520
[3]  
Chan JD, 1998, PHARMACOTHERAPY, V18, P1304
[4]  
FEDELI L, 1989, CANCER, V64, P1805, DOI 10.1002/1097-0142(19891101)64:9<1805::AID-CNCR2820640908>3.0.CO
[5]  
2-D
[6]   Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders [J].
Foot, ABM ;
Veys, PA ;
Gibson, BES .
BONE MARROW TRANSPLANTATION, 1999, 24 (10) :1089-1093
[7]   Severe vincristine toxicity in combination with itraconazole [J].
Gillies, J ;
Hung, KA ;
Fitzsimons, E ;
Soutar, R .
CLINICAL AND LABORATORY HAEMATOLOGY, 1998, 20 (02) :123-124
[8]   FLUCONAZOLE - AN UPDATE OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN MAJOR SUPERFICIAL AND SYSTEMIC MYCOSES IN IMMUNOCOMPROMISED PATIENTS [J].
GOA, KL ;
BARRADELL, LB .
DRUGS, 1995, 50 (04) :658-690
[9]   ITRACONAZOLE - A REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES, AND THERAPEUTIC USE IN SUPERFICIAL AND SYSTEMIC MYCOSES [J].
GRANT, SM ;
CLISSOLD, SP .
DRUGS, 1989, 37 (03) :310-344
[10]  
LEVRON JC, 1997, PHARMACOKINETIC STUD